Dosimetry of [18F]Fluoro-pivalic acid ([18F]FPIA) PET Tracer: Human dose estimates based on balb/c biodistribution data

Document Type : Original Article

Authors

1 Department of Medical Radiation Engineering, Faculty of Nuclear Engineering, Shahid Beheshti University, Tehran, Iran

2 Radiation Application Research School, Nuclear Science and Technology Research Institute, Tehran, Iran

Abstract

Introduction: [18F]Fluoro-pivalic acid ([18F]FPIA) is a PET radiotracer under investigation for imaging short-chain fatty acid (SCFA) metabolism in gliomas. Accurate human radiation dosimetry is a prerequisite for its clinical translation. This study aimed to estimate human organ absorbed doses of [18F]FPIA based on biodistribution data obtained from normal BALB/c mice.
Methods: [18F]FPIA was synthesized at the Karaj Cyclotron Center (Karaj, Iran) via nucleophilic fluorination of a tosyl precursor. For biodistribution studies, female BALB/c mice (n=3 per time point, total n=9) were intravenously injected with 0.526 mCi (19.46 MBq). Animals were sacrificed at 15, 30, and 60 minutes post-injection. Radioactivity in major organs was measured using a well-type NaI(Tl) detector and expressed as percentage of injected dose per gram (%ID/g). Time-activity curves were generated via trapezoidal integration and exponential fitting. Cumulative organ activities were calculated and extrapolated to humans using the Sparks–Aydogan mass scaling method. Human organ absorbed doses and the effective dose were estimated using the Medical Internal Radiation Dose (MIRD) formalism implemented in OLINDA/EXM 2.0 software.
Results: The highest estimated absorbed doses in human organs were observed in the bladder wall (0.201 mGy/MBq) and kidneys (0.143 mGy/MBq). In contrast, the brain (0.0274 mGy/MBq) and intestines (0.0196 mGy/MBq) received the lowest doses. The estimated effective dose was 0.016 mSv/MBq.
Conclusion: The dosimetry profile of [18F]FPIA, characterized by low background brain exposure and favorable dose estimates comparable to other clinical 18F-tracers, supports its safe application for PET imaging. These results facilitate the clinical translation of [18F]FPIA for tracing SCFA metabolism in glioma studies.

Keywords

Main Subjects

References

  1. Lin S, Xu H, Zhang A, Ni Y, Xu Y, Meng T, Wang M, Lou M. Prognosis analysis and validation of m6A signature and tumor immune microenvironment in glioma. Front Oncol. 2020 Oct 5;10:541401.
  2. Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro Oncol. 2012 Nov;14 Suppl 5(Suppl 5):v1-49.
  3. Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. JAMA. 2013 Nov 6;310(17):1842-50.
  4. Ostrom QT, Gittleman H, Xu J, Kromer C, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2009–2013. Neuro Oncol. 2016 Oct 1;18(suppl_5):v1-v75.
  5. Overcast WB, Davis KM, Ho CY, Hutchins GD, Green MA, Graner BD, Veronesi MC. Advanced imaging techniques for neuro-oncologic tumor diagnosis, with an emphasis on PET-MRI imaging of malignant brain tumors. Curr Oncol Rep. 2021 Feb 18;23(3):34.
  6. Baenke F, Peck B, Miess H, Schulze A. Hooked on fat: the role of lipid synthesis in cancer metabolism and tumour development. Dis Model Mech. 2013 Nov;6(6):1353-63.
  7. Oyama N, Akino H, Kanamaru H, Suzuki Y, Muramoto S, Yonekura Y, Sadato N, Yamamoto K, Okada K. 11C-acetate PET imaging of prostate cancer. J Nucl Med. 2002 Feb;43(2):181-6.
  8. Ponde DE, Dence CS, Oyama N, Kim J, Tai YC, Laforest R, Siegel BA, Welch MJ. 18F-fluoroacetate: a potential acetate analog for prostate tumor imaging--in vivo evaluation of 18F-fluoroacetate versus 11C-acetate. J Nucl Med. 2007 Mar;48(3):420-8.
  9. Witney TH, Alam IS, Turton DR, Smith G, Carroll L, Brickute D, Twyman FJ, Nguyen QD, Tomasi G, Awais RO, Aboagye EO. Evaluation of deuterated 18F- and 11C-labeled choline analogs for cancer detection by positron emission tomography. Clin Cancer Res. 2012 Feb 15;18(4):1063-72.
  10. Clark PM, Mai WX, Cloughesy TF, Nathanson DA. Emerging approaches for targeting metabolic vulnerabilities in malignant glioma. Curr Neurol Neurosci Rep. 2016 Feb;16(2):17.
  11. Lin H, Patel S, Affleck VS, Wilson I, Turnbull DM, Joshi AR, Maxwell R, Stoll EA. Fatty acid oxidation is required for the respiration and proliferation of malignant glioma cells. Neuro Oncol. 2017 Jan;19(1):43-54.
  12. Pike LS, Smift AL, Croteau NJ, Ferrick DA, Wu M. Inhibition of fatty acid oxidation by etomoxir impairs NADPH production and increases reactive oxygen species resulting in ATP depletion and cell death in human glioblastoma cells. Biochim Biophys Acta. 2011 Jun;1807(6):726-34.
  13. Verger A, Kas A, Darcourt J, Guedj E. PET imaging in neuro-oncology: An update and overview of a rapidly growing area. Cancers. 2022 Feb 22;14(5):1103.
  14. Mashimo T, Pichumani K, Vemireddy V, Hatanpaa KJ, Singh DK, Sirasanagandla S, Nannepaga S, Piccirillo SG, Kovacs Z, Foong C, Huang Z, Barnett S, Mickey BE, DeBerardinis RJ, Tu BP, Maher EA, Bachoo RM. Acetate is a bioenergetic substrate for human glioblastoma and brain metastases. Cell. 2014 Dec 18;159(7):1603-14.
  15. Snyder WS, Ford MR, Warner GG, Watson S. MIRD pamphlet no. 11: S, absorbed dose per unit cumulated activity for selected radionuclides and organs. New York: Society of Nuclear Medicine. 1975.
  16. Shanehsazzadeh S, Lahooti A, Yousefnia H, Geramifar P, Jalilian AR. Comparison of estimated human dose of (68)Ga-MAA with (99m)Tc-MAA based on rat data. Ann Nucl Med. 2015 Oct;29(8):745-53.
  17. Hu LS, Hawkins-Daarud A, Wang L, Li J, Swanson KR. Imaging of intratumoral heterogeneity in high-grade glioma. Cancer Lett. 2020 May 1;477:97-106. doi: 10.1016/j.canlet.2020.02.025. Epub 2020 Feb 27. PMID: 32112907; PMCID: PMC7108976.
  18. Albert NL, Weller M, Suchorska B, Galldiks N, Soffietti R, Kim MM, la Fougère C, Pope W, Law I, Arbizu J, Chamberlain MC, Vogelbaum M, Ellingson BM, Tonn JC. Response assessment in neuro-oncology working group and European association for neuro-oncology recommendations for the clinical use of PET imaging in gliomas. Neuro Oncol. 2016 Sep;18(9):1199-208.
  19. Mohammadi BM, Shirmardi SP, Shokri AA, Erfani M. Estimation of organ-absorbed doses in human from gamma rays of 99mTc-DTPA radiopharmaceutical, using the animal dissection data. Arch Adv Biosci. 2019 Nov 26;10(4):22-30.
  20. Vassileva V, Braga M, Barnes C, Przystal J, Ashek A, Allott L, Brickute D, Abrahams J, Suwan K, Carcaboso AM, Hajitou A. Effective detection and monitoring of glioma using [18F] FPIA PET imaging. Biomedicines. 2021 Jul 13;9(7):811.
  21. Pisaneschi F, Witney TH, Iddon L, Aboagye EO. Synthesis of [18 F] fluoro-pivalic acid: an improved PET imaging probe for the fatty acid synthesis pathway in tumours. Med chem comm. 2013;4(10):1350-3.
  22. Witney TH, Pisaneschi F, Alam IS, Trousil S, Kaliszczak M, Twyman F, Brickute D, Nguyen QD, Schug Z, Gottlieb E, Aboagye EO. Preclinical evaluation of 3-18F-fluoro-2,2-dimethylpropionic acid as an imaging agent for tumor detection. J Nucl Med. 2014 Sep;55(9):1506-12.
  23. Dubash SR, Keat N, Kozlowski K, Barnes C, Allott L, Brickute D, Hill S, Huiban M, Barwick TD, Kenny L, Aboagye EO. Clinical translation of 18F-fluoropivalate - a PET tracer for imaging short-chain fatty acid metabolism: safety, biodistribution, and dosimetry in fed and fasted healthy volunteers. Eur J Nucl Med Mol Imaging. 2020 Oct;47(11):2549-61.
  24. Shanehsazzadeh S, Gruettner C, Lahooti A, Mahmoudi M, Allen BJ, Ghavami M, Daha FJ, Oghabian MA. Monoclonal antibody conjugated magnetic nanoparticles could target MUC-1-positive cells in vitro but not in vivo. Contrast Media Mol Imaging. 2015 May-Jun;10(3):225-36.
  25. Jalilian AR, Shanehsazzadeh S, Akhlaghi M, Garousi J, Rajabifar S, Tavakoli MB. Preparation and biodistribution of [Ga-67]-DTPA-gonadorelin in normal rats. J Radioanal Nucl Chem.2008;278(1):123-9.
  26. Bolch WE, Eckerman KF, Sgouros G, Thomas SR. MIRD pamphlet No. 21: a generalized schema for radiopharmaceutical dosimetry--standardization of nomenclature. J Nucl Med. 2009 Mar;50(3):477-84.
  27. Khorrami Moghaddam A, Reza Jalilian A, Hayati V, Shanehsazzadeh S. Determination of human absorbed dose of 201Tl(III)-DTPA-HIgG based on biodistribution data in rats. Radiat Prot Dosimetry. 2010 Oct;141(3):269-74.
  28. Sparks RB, Aydogan B. Comparison of the effectiveness of some common animal data scaling techniques in estimating human radiation dose. Oak Ridge Associated Universities, 1999 Jan 1; TN, United States.
  29. Bevelacqua JJ. Internal dosimetry primer. Radiat Prot Manag. 2005 Jan 1;22(5):7.
  30. Xie T, Lee C, Bolch WE, Zaidi H. Assessment of radiation dose in nuclear cardiovascular imaging using realistic computational models. Med Phys. 2015 Jun;42(6):2955-66.

Files

Share

How to cite

Statistics